

August 07, 2017

The National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex, Bandra (E)
Mumbai - 400051

The Bombay Stock Exchange Limited
15th Floor, Phiroze Jeejeeboy Towers
Dalal Street,
Mumbai – 400001

Subject: Press Release for Unaudited Financial Results for the Quarter ended June 30, 2017

Dear Sir/Madam,

Please find enclosed herewith the Press Release for the Unaudited Financial Results (Standalone and Consolidated) for the Quarter ended June 30, 2017.

You are requested to take note of the above.

Thanking You,

Yours Faithfully,

For **Dr. Lal PathLabs Limited**



Rajat Kalra

Company Secretary & Legal Head



Encl: As above

Dr. Lal PathLabs Limited records revenue growth of 12% in Q1FY2017-18

New Delhi, India, Aug 7, 2017 – Dr. Lal PathLabs Limited (referred to as the “Company”; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended June 30, 2017

Consolidated Performance Highlights: Q1FY2017-18 vs. Q1FY2016-17
Revenue growth: 12% Normalised EBITDA growth: 11%, Normalised EBITDA margin maintained at 27.3%

- Operating Revenue increased by 11.9% in Q1 to Rs. 2493 million vs Rs 2228 million in the previous year same quarter. Underlying volume growth is 9.1% during the quarter.
- Normalised EBITDA increased by 11% in Q1FY18 to Rs.680 million from Rs 613 million in the same quarter last year, after adjusting for ESOP and other stock based compensation costs.
- EBITDA Margin was 27.3% for Q1 FY18 vs 27.5% in Q1 FY17. Consequently PBT was higher by 9.2% in Q1
- Profit after Tax in Q1 has improved by 11.7% to Rs. 446 million in Q1FY18 from Rs 399 million in Q1 FY17

Financial Overview (Consolidated) in Rs mn

(Rs. Mn.)					
Particulars	JQ FY 17	JQ FY 16	Gr %	FY'17 Ind AS	FY'17 IGaap
Total Revenue	2,492.6	2,228.4	11.9%	9,123.8	9,123.8
Total Expenditure	1,837.4	1,622.9		6,749.2	6,758.4
EBITDA	655.2	605.4	8.2%	2,374.6	2,365.4
RSU and stock based comp. cost	24.8	7.4		86.1	80.5
Normalised EBITDA excl RSU	680.0	612.8	11.0%	2,460.7	2,445.9
<i>Normalised Margins</i>	<i>27.3%</i>	<i>27.5%</i>		<i>27.0%</i>	<i>26.8%</i>
Other income incl interest	74.6	64.4	15.9%	275.2	251.3
PBT	660.3	604.9	9.2%	2,367.3	2,333.0
<i>Margins</i>	<i>26.5%</i>	<i>27.1%</i>		<i>25.9%</i>	
PAT	445.5	398.9	11.7%	1,547.7	1,551.9
<i>Margins</i>	<i>17.9%</i>	<i>17.9%</i>		<i>17.0%</i>	<i>17.0%</i>
EPS (Basic)	5.42	4.88	10.9%	18.92	18.62
EPS (Diluted)	5.41	4.85	11.5%	18.85	18.55

Figures have been recast as per Ind AS requirements



About Dr. Lal PathLabs Limited

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

Dr. Lal PathLabs has built a national, “hub and spoke” network that includes its National Reference Laboratory in New Delhi, 188 other clinical laboratories, 1,759 patient service centers and 5,021 pickup points as of March 31, 2017. Their customers include individual patients, hospitals and other healthcare providers and corporate customers.

Contact Details

Dilip Bidani
Dr. Lal PathLabs Limited

+91 124 3016500
cfo@lalpathlabs.com

Aparna Agarwal
Adfactors PR

+91 9811177405
aparna.agarwal@adfactorspr.com

For further information on Dr. Lal PathLabs see www.lalpathlabs.com

Safe Harbour

This release contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr. Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr. Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.